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Summary 
 
Aim: 
Blauvelt et al. (The Lancet 2017; 389: 2287-303) aimed to compare the long-term efficacy and 
safety of dupilumab with medium-potency topical corticosteroids (TCS) versus placebo with 
TCS in adults with moderate-to-severe atopic dermatitis (AD).  
Setting and design: 
This multicentre randomised, double-blinded, placebo-controlled trial was conducted in 
hospitals, clinics and academic institutions across 161 sites in 14 countries.  
Study exposure: 
Adults with moderate-to-severe AD were randomly assigned (3:1:3) to receive subcutaneous 
dupilumab 300mg once weekly (qw) plus TCS, dupilumab 300mg every 2 weeks (q2w) plus 
TCS, or placebo plus TCS until week-52.  
Primary outcome measures: 
Co-primary efficacy endpoints were patients (%) achieving Investigator’s Global Assessment 
(IGA) 0/1 and 2-points or higher improvement from baseline, and Eczema Area and Severity 
Index 75% improvement from baseline (EASI-75) at week-16. 
Results: 
 
740 patients were included in the trial: 319 were randomly assigned to dupilumab qw, 106 to 
dupilumab q2w and 315 to the placebo arm. At week-16, more patients in the dupilumab 
groups achieved the co-primary endpoints: IGA 0/1 (39% [125 patients] qw dosing, 39% [41 
patients] q2w dosing vs 12% [39 patients] receiving placebo; p<0.0001) and EASI-75 (64% 
[204] and 69% [73] vs 23% [73]; p<0.0001). Whilst no new safety signals were identified, 
adverse effects (AEs) were noted in 261 (83%) in those receiving dupilumab qw plus TCS, 97 
(88%) dupilumab q2w plus TCS and 266 (84%) for placebo plus TCS. Rates of conjunctivitis, 
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injection site reactions and local herpes simplex infections were higher in the dupilumab 
groups compared with placebo.  
Conclusions: 
 
Blauvelt et al. concluded that dupilumab treatment added to TCS improved AD up to week-
52 compared with TCS alone, and also demonstrated acceptable safety.  
 
 
Comment 
 
What is already known about this topic? 
 
Atopic dermatitis (AD, syn. eczema, atopic eczema) is a chronic, pruritic inflammatory skin 
disorder primarily affecting children, but sometimes persisting, re-emerging or starting in 
adulthood with an estimated world prevalence in adults of 2-11.5%.1-3 Severe disease can be 
very disabling and has been associated with chronic pruritus, sleep disturbance, reduced 
quality of life, anxiety and depression.4,5 
Most cases of AD typically respond well to appropriate use of emollients plus topical 
anti-inflammatory treatments (TCS and/or topical calcineurin inhibitors [TCI]), but severe 
disease and some cases of moderate disease may require longer term potent TCS. This could 
lead to side-effects such as skin thinning if used inappropriately, e.g. due to continued use on 
sensitive sites such as the face. Narrowband UVB phototherapy is an established adjunct in 
the treatment of moderate-to-severe AD.6 Systemic immunosuppressive medications are 
usually reserved for chronic severe AD not responding to other treatments. Ciclosporin 
remains the only licensed treatment for refractory AD in many European countries. Studies 
have shown a mean clinical improvement between 53% and 95% using different clinical 
severity scores after short-term treatment, however prolonged use is associated with 
hypertension, renal impairment and a possible increased risk of cancer.7-15 Evidence for other 
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systemic immunosuppressant treatment is more limited, but methotrexate (mean SCORAD 
[SCORing of Atopic Dermatitis] improvement: 42%; SCORAD 50% improvement from baseline 
[SCORAD-50]: 40%), azathioprine (mean SCORAD improvement: 39%; SCORAD-50: 45%) and 
mycophenolate (shown to be equally effective as ciclosporin in one small study but without 
data on SCORAD % improvement from baseline values) are also used.6,8,16-20 Evidence for 
effectiveness of current systemic treatments in severe AD is modest and monitoring is 
required due to the risk of AEs.8 Development of more efficacious treatments for severe AD 
with a better safety profile is therefore welcome, especially if shown to be cost-effective.  
Dupilumab is the first US Food and Drug Administration (FDA)-approved biologic 
treatment for moderate-to-severe AD and is a fully human monoclonal antibody. It binds to 
the alpha subunit of the interleukin-4-receptor, which inhibits signalling from interleukin-4 
and interleukin-13.21 Aside from AD, its efficacy and safety have been demonstrated in 
patients with other atopic conditions, including asthma and chronic rhinosinusitis.22,23 
Simpson et al. demonstrated short-term efficacy at week-16 in patients with moderate-to-
severe AD (IGA 3-4) in two placebo-controlled randomised trials (SOLO 1 and SOLO 2) but did 
not assess longer term outcomes.24 The LIBERTY AD CHRONOS trial aimed to provide evidence 
on long-term efficacy and safety of dupilumab at a dose of 300mg given once weekly or every 
2 weeks in adults with moderate-to-severe AD up to 52 weeks in a phase 3 randomised trial.25   
 
Strengths of the research 
 
This is the first study to assess long-term efficacy and safety of dupilumab treatment for 
moderate-to-severe AD in adults and the authors are to be commended for conducting an 
appropriate length study in such a chronic disease that requires long-term maintenance 
treatment for disease suppression.  
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In contrast to the SOLO 1 and 2 studies, patients were advised to continue regular use 
of topical treatments where required (TCS or TCI if use of TCS was inadvisable) in both active 
and placebo arms. The authors suggested that use of TCS/TCI provided a more pragmatic 
approach, aiming to mirror standard care. The range of secondary outcomes are sufficient in 
this study and include a variety of important clinician and patient-reported measures. 
As expected with a publication in The Lancet, the study is well reported with good 
adherence to CONSORT guidelines,26 including: (i) a clear abstract which includes the study 
aim and relevant outcomes, (ii) clearly described settings and methodology, expanded in the 
appendix, (iii) use of a table to display baseline characteristics, and (iv) a CONSORT flow 
diagram to show the phases of parallel groups from screening through to study completion. 
The trial was pre-registered on ClinicalTrials.gov. The study was industry sponsored and the 
funder participated in the design, analysis, drafting, revision, and approval of the submitted 
paper. Conflicts of interest were declared for all 31 authors, 16 of whom had a financial 
conflict with the commercial sponsors.  
 
Assessment of validity 
 
Internal validity 
We used the Cochrane risk of bias framework to assess internal validity.27 
 
Randomisation (selection bias) 
Patients were randomised in a ratio of 3:1:3 to dupilumab 300mg qw +TCS; dupilumab 300mg 
q2w +TCS; placebo +TCS, respectively using a central randomisation scheme that was 
provided by an interactive voice/web response system which ensures allocation concealment 
and minimises risk of selection bias. The patients were stratified by baseline disease severity 
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and geographical location ensuring uniformity between groups. Although details on the 
method of random sequence generation were not given, the method used was likely to have 
been robust and consequently we determined the risk of selection bias to be low. 
 
Blinding (performance bias and detection bias) 
The study design included adequate blinding to patients, study personnel and outcome 
assessors, until the pre-specified unblinding following a database lock. The authors state that 
the statistician who provided the randomisation sequence was unblinded. We are uncertain 
of the significance of this without further information: in theory, the integrity of the trial could 
be threatened if the statistician was not external to the sponsors and was involved in 
discussions about changes in trial design while the trial was ongoing. The authors describe 
identical study drug kits and protocols for the 3 study arms, and the placebo syringes were 
identical to the dupilumab syringes, minimising the risks of any performance and detection 
biases, which we rated as low overall.   
 
Intention to treat (attrition bias) 
Intention to treat (ITT) analysis was used for the co-primary binary endpoints. The authors 
stated that patients were recorded as non-responders after rescue treatment initiation or 
study withdrawal. At week-16, when the co-primary endpoints were assessed, there were 
very few dropouts across groups, resulting in a low risk of attrition bias for these outcomes. 
By week-52 however, there was a higher proportion of dropouts in the placebo group (33% 
vs 14% and 15% dropout rate in the two active dupilumab groups). The authors suggest that 
higher dropouts in the placebo group may be related to increased satisfaction with dupilumab 
treatment. 
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Continuous efficacy endpoints were analysed by multiple approaches including the 
last observation carried forward (LOCF) method with an analysis of covariance (ANCOVA) 
model (a statistical tool that sits between analysis of variance and regression analysis). 
Additional sensitivity analyses were performed and detailed in the appendix, including a 
multiple imputation approach with ANCOVA (continuous endpoints) and post-baseline LOCF 
(binary endpoints). Imputation refers to a statistical method used to estimate missing 
outcome data using other available data to infer the missing values and conform to ITT.28  All 
these analyses supported the results from the primary analyses; therefore, we judged the 
overall risk of attrition bias as low. 
 
Selective reporting (reporting bias) 
All the outcomes stated in the trial register (published before the start of the study, 
ClinicalTrials.gov ID NCT02260986) were reported in the final publication and we have rated 
the risk of reporting bias as low. However, one deviation was noted whereby The Lancet 
publication reports on two co-primary endpoints whereas only the IGA endpoint was 
registered on ClinicalTrials.gov as a primary endpoint. Although no explanation is given in the 
article or trial register for the apparent deviation, the published study protocol reports that 
the European Union and Japanese centres had requested that EASI-75 was added as a co-
primary endpoint. The European Clinical Trials Register (EudraCT number 2013-003254-24) 
recorded both endpoints as co-primaries.  
 
Power 
The sample size calculation estimated that 300, 100 and 300 patients in the dupilumab 300mg 
qw, dupilumab 300mg q2w and placebo groups would be needed, respectively. Further 
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details, presented in the appendix, explained that the study provided 99% power to detect a 
difference of 29% in the IGA primary endpoint for comparisons between dupilumab groups 
and placebo. Although the accompanying appendix stated that the sample size was chosen to 
“enable adequate characterization of the long-term safety profile” (without giving further 
details), the very high power of 99% (normally set at 90%) seems excessive, as there are 
ethical concerns about a study that is unnecessarily large. The authors also state that the 
study was not powered to compare endpoints between the two dupilumab groups, which 
begs the question of why two dupilumab groups were tested in this study? 
The power calculation was based on comparing the primary endpoints at week-16, 
using results from a previous phase 2 dupilumab study.24 It could be argued that the study 
should have been powered to detect differences at 52 weeks as the authors stated the study 
rationale was to assess long-term efficacy and not efficacy at 16 weeks. No adjustment for 
the level of statistical significance is reported for the introduction of the additional primary 
outcome following trial registration. 
 
External Validity 
The study population included adults with moderate-to-severe AD (diagnosed by American 
Academy of Dermatology Consensus Criteria)29 with an “inadequate response to medium-
potency to high-potency TCS (with or without TCI as appropriate)”. This was defined further 
in the appendix where it stated it represents: “failure to achieve and maintain remission or a 
low disease activity state… despite treatment with a daily regimen of TCS of medium to high 
potency, applied for at least 28 days or for the maximum duration recommended by the 
product prescribing information (e.g. 14 days of super-potent TCS)”. How this definition 
(which could include someone with moderate AD who failed to achieve low disease activity 
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after using only a medium potency TCS for 28 days) was operationalised i.e. whether all 
potential study patients were given a “proper” course of TCS treatment, or whether it was a 
subjective decision left to the discretion of the paid recruiting doctor is not clear. In practice 
potent and super-potent TCS are often used for longer periods than described in this study.30 
Over half (53%) of study patients had moderate AD (IGA 3) and given that systemic 
treatment is usually reserved for severe cases who have the greatest unmet clinical need, we 
question the rationale for including moderate disease at all. A large number of private 
dermatology clinics were involved in recruiting to the study (investigators and sites detailed 
in the appendix), and this may explain why moderate AD patients make up the majority. The 
inclusion of this large proportion of moderate AD patients may also explain the significant 
improvement in endpoints observed in the placebo arm, above what might normally be 
expected in an AD trial of those with severe disease. 
 We believe the inclusion of such a large proportion of moderate AD patients impacts 
significantly on the study’s external validity and whether it really addresses the correct 
population who require biologic treatment in clinical practice. It is worth noting that patients 
with moderate AD represent a much larger potential market for the manufacturers. As a 
minimum, we would have expected a planned subgroup analysis of the moderate and severe 
patients separately, but unfortunately this was not the case, and no post-hoc subgroup 
analysis was shown - data that we and guideline writers would need before recommending 
such a systemic treatment for those with severe disease. 
A large number of outcomes were measured in this study, covering all of the core 
outcome domains agreed by the international Harmonising Outcome Measures in Eczema 
(HOME) initiative, namely “clinical signs (physician assessed)”, “symptoms (patient 
assessed)”, “quality of life” and “long-term control of disease”.31 The measures used to assess 
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these domains include the core outcome measures agreed by the HOME initiative: EASI and 
POEM (patient oriented eczema measure). The authors are to be commended for including 
such core outcomes which will facilitate comparability of this study in a meta-analysis with 
others that use core outcomes. The EASI score, a well validated and sensitive objective AD 
outcome measure,32 assesses the severity and extent of: erythema; induration; papulation 
and oedema; excoriations; and lichenification with a score ranging from 0 to 72. The use of 
the IGA as a co-primary endpoint should be interpreted with caution as it is limited by lack of 
standardisation and no consideration of disease extent (e.g. no body surface area).33 However 
the authors can be forgiven as the FDA recommends the use of such an unvalidated global 
assessment as the primary endpoint for new drug approval trials in AD for reasons that are 
unclear; hence its almost universal use in dermatology trials in the US.33  
In assessing long-term disease control, the study recorded objective and subjective 
outcomes at 4 weekly intervals, proportion of topical and systemic rescue medication-free 
days and incidence rate of flares (defined as worsening of AD requiring escalation or 
intensification of treatment). There are inherent challenges in studying a chronic, intermittent 
disease such as AD and consequently defining long-term disease control is difficult, with no 
widely accepted or validated measure34 – a challenge that is currently being addressed by the 
HOME group.  
 
Other issues 
The authors may have introduced some subtle “framing bias” through the way in which 
systemic medications were referred to negatively with comments such as their “long-term 
use…is not recommended, due to risk of serious toxicities”- with little evidence backing this 
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up. It is true that existing systemic treatments for AD require monitoring, but most appear 
safe when used in adherence to treatment guidelines.8 
There was also an impressive number of centres and principal investigators involved 
across multiple continents (161 sites in 14 countries). Whilst this may have helped maximise 
recruitment activity, such an approach, along with concerns that the study might have been 
overpowered at 99% rather than the conventional 90%, raises concerns that some degree of 
“seeding” was planned with this study. Seeding refers to the testing of a drug in a large 
number of centres and countries in order to promote confidence and familiarity in the study 
drug; in the hope that clinicians endorse the drug following study completion.35 
Although the study design was robust, we have to question why there was no active 
comparator group given that safety and efficacy for dupilumab has already been 
demonstrated in two placebo-controlled studies.24 Is this a fair test of a new biologic? We are 
not convinced it is. We were also disappointed to see no planned active comparator trials 
when we searched the main trial register (www.ClinicalTrials.gov, accessed 2nd October 2017). 
If regulatory bodies such as the National Institute for Health and Care Excellence (NICE) are 
going to assess dupilumab, they will want to see evidence of how it compares with existing 
systemic treatment (in terms of an unbiased estimate of efficacy, safety, convenience and 
cost-effectiveness). However, given that it is not in industry’s interests to take the risk of 
evaluating comparative efficacy and cost-effectiveness against cheaper active comparators,36 
it is likely that we will have to wait for a non-industry sponsored study before dupilumab’s 
true comparative efficacy, safety and cost against the other systemic drugs are known. 
Network meta-analysis is another approach that might be used in the meantime.37 
 
Overall assessment (including any potential application of the research to clinical practice) 
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This study reinforces the 16-week efficacy and safety outcomes from SOLO 1 and 2 and goes 
further to demonstrate maintained efficacy and safety up to week-52 of treatment. The 
findings demonstrate dupilumab was generally well tolerated in this study with no new safety 
concerns. It is however too early to determine rarer AEs, which may be picked up during 
ongoing monitoring after its licence.38 This study confirmed a strong association of dupilumab 
with conjunctivitis, occurring in 17.9% of treated patients. This was mild in the majority of 
cases and appears to be specific to AD as it has not been identified in other conditions treated 
with dupilumab.22,23 Patients should be closely monitored to detect this at an early stage, in 
particular those with more severe symptoms.  
Our appraisal has shown that the risk of bias appears to be low in this study with no 
major concerns regarding internal validity. Our major concerns resided with the external 
validity of the study - the inclusion of AD patients with moderate disease and the lack of 
subgroup analysis for those with severe AD where most interest in systemics reside. We also 
feel uncomfortable about the ethical rationale of asking patients with “an inadequate 
response to topical corticosteroids” to be randomised to a control group of TCS plus placebo 
for a whole year. Whilst continued use of TCS better reflects real-world practice, it was 
surprising that patients on weekly dupilumab were still requiring TCS or systemic rescue 
therapy 66.3% (100 minus 33.3%) of the time over 52 weeks. It may be argued that the whole 
point of using systemics is to be free of the daily toil of applying topical therapies. We 
calculated the number needed to treat (NNT) for dupilumab as 3.7 (39% achieved IGA 0/1 vs 
12%) which is a reasonable magnitude of benefit for patients receiving this drug, although it 
needs to be borne in mind that the study drug was compared against placebo rather than an 
active comparator, and few of us use placebo injections in clinical practice. 
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It is unfortunate that despite testing two different dupilumab dose regimens (300mg 
once weekly or every 2 weeks) which produced very similar results, the authors remained 
silent on which regimen would be preferred. Thankfully, the clear reporting of the study 
accompanied by the large study power allows us to estimate and interpret these differences 
for ourselves. For the outcome of IGA 0/1 at week-16, the difference in proportions between 
dupilumab once weekly and every 2 weeks was 0.5% in favour of once weekly (39.18% minus 
38.68% i.e. trivial difference), with a corresponding 95% confidence interval with continuity 
correction of -10.82% (i.e. every 2 weeks up to 10.82% better) to +11.25% (i.e. once weekly 
up to 11.25% better). For EASI-75, the difference in proportions between dupilumab once 
weekly and every 2 weeks was 4.92% in favour of dupilumab every 2 weeks (68.87% minus 
63.95%), with a 95% confidence interval ranging from -6.22% in favour of once weekly to 
+15.03% in favour of every 2 weeks. We conclude that dupilumab used every 2 weeks is 
probably just as effective as when it is used once weekly, but at half the cost and potentially 
less long-term toxicity.  
On the whole, the authors should be praised for their study conduct and reporting, 
which demonstrated longer term benefit and safety of dupilumab. Clinicians such as ourselves 
welcome further treatment options with good efficacy and few side-effects for managing 
severe AD, particularly in cases where other systemic treatments have failed. What is now 
needed are studies that compare dupilumab against existing systemic treatments such as 
methotrexate in people with severe AD or for those who have failed on phototherapy and 
one other systemic. Longer term data beyond one year will also be important for patients 
entering into this length of treatment as it is not clear whether dupilumab needs to be 
continued indefinitely or whether it can be stopped or used intermittently to maintain 
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remission, and whether such long-term strategies will be safe. Cost-effectiveness has also 
received little attention so far and we welcome modelling of such data by bodies such as NICE.  
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